CLINICAL TRIALS FOR NEW ARTHRITIS TREATMENT.
Crawford Dog and Cat Hospital is participating in a veterinary pharmaceutical drug trial to assist the USA registration of a new drug designed to help control the clinical signs associated with osteoarthritis in dogs. The investigational drug is not currently FDA approved, but is approved for use in other markets around the work, including Australia and New Zealand.
We are inviting Long Island dog owners to nominate their dogs for inclusion in this clinical trial. The formal component of the trial is designed to run over a seven to eleven week period, depending on your dog's response to treatment. following successful completion of the initial trial period, participants have the option to continue their involvement with an at-home assessment.
OSTEOARTHRITIS IN DOGS.
Cartilage is a smooth, resilient tissue that lines all joints, allowing nearly frictionless joint movement and providing shock absorption. Canine Osteoarthritis (OA) is a degenerative joint disease (DJD) that results in the loss of joint cartilage and synovial fluid. Deterioration of joint cartilage and joint fluid leads to increased friction and inflammation in the joints which is accompanied by pain and loss off range of motion of the joint in dogs. DJD can also result in the formation of bone spurs which interfere with normal joint movement and cause pain. Eventually, the joint cartilage can be eroded to the extent that underlying subchondral bone is exposed and rubs against adjacent subchondral bone. because subchondral bone is rich in nerve supply, exposed bone is a significant source of joint pain in dogs with OA.
CLINICAL SIGNS OF OSTEOARTHRITIS IN DOGS.
- Some difficulty rising after a period of rest
- Stiffness after vigorous activity
- Difficulty with stairs
- Difficulty jumping in our out of car.
- Difficulty or reluctance to jump on or off of furniture
- Change of in character or onset of aggression
- Swollen, warm joints with licking or chewing at affected joints.
- Limping or holding up a limb or limbs.
OSTEOARTHRITIS MANAGEMENT IN DOGS
Traditionally, veterinary management of canine OA has been reactive when a dog has symptoms of osteoarthritis. It often involves disease management to alleviate the animal's pain and discomfort, usually involving the prescription of a symptom modifying, non-steroidal anti-inflammatory drug (NSAID) such as Rimadyl, Deramaxx, or Metacam.
The investigational osteoarthritis drug to be evaluated is registered in overseas markets to control the clinical signs associated with arthritis in dogs. The beneficial effects of the investigational drug in DJD are believed to be due to the following actions:
- Increase in cartilage production by stimulating cartilage-producing cells
- increase in the volume and quality of the lubricating joint fluid
- Protection of cartilage from damage by inhibiting enzymes that excessively degrade cartilage
- Improved blood circulation to the subchondral bone
The objective of this trial is to provide evidence of effectiveness as well as the duration of effectiveness of this new investigational drug for the control of clinical signs associated with osteoarthritis in dogs unde conditions of use in veterinary practice in the USA. The data will be used to support FDA approval.
The selection requirements for inclusion in this clinical trial are quite specific. If you wish to nominate your pet for inclusion, please use the client feedback form.
Please include any questions you might have about the study or the investigational drug and one of our team will respond.